Pheochromocytoma and paraganglioma: Progress on all fronts

Endocrine Pathology

Volumn 23, Issue 1, 2012, Pages 1-3

  Gimenez Roqueplo, Anne Paule ^a,b,c   Tischler, Arthur S ^d  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^d TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN; PROTEIN NF1; PROTEIN RET; SUCCINATE DEHYDROGENASE; TRANSCRIPTOME; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

BENIGN TUMOR; COMORBIDITY; CONSENSUS; EDITORIAL; ENZYME SUBUNIT; FAMILIAL CANCER; FOLLOW UP; FRANCE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; GENOTYPE PHENOTYPE CORRELATION; IMMUNOHISTOCHEMISTRY; METASTASIS; PARAGANGLIOMA; PATIENT CARE; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SYMPOSIUM; TUMOR LOCALIZATION; TUMOR VOLUME;

ADRENAL GLAND NEOPLASMS; HUMANS; PARAGANGLIOMA; PHEOCHROMOCYTOMA;

EID: 84855586595     PISSN: 10463976     EISSN: 15590097     Source Type: Journal    
DOI: 10.1007/s12022-011-9190-7     Document Type: Editorial

References (17)

1. Eisenhofer G, Schott M, Bornstein S. Pheochromocytoma and paraganglioma: recent progress and new vistas for improved patient care. Horm Metab Res 2012; 44: in press
2. Amar L, Fassnacht M, Gimenez-Roqueplo AP, Januszewicz A, Prejbisz A, Timmers H, Plouin PF. Long-term postoperative follow-up in patients with apparently benign pheochromocytoma and paraganglioma. Horm Metab Res 2012; 44: in press
3. Buffet A, Venisse A, Nau V, Roncellin I, Boccio V, Le Pottier N, Boussion M, Travers C, Simian C, Burnichon N, Abermil N, Favier J, Jeunemaitre X, Gimenez-Roqueplo AP. A decade (2001-2010) of genetic testing for pheochromocytoma and paraganglioma. Horm Metab Res 2012; 44: in press
4. Eisenhofer G, Vocke CD, Elkahloun A, Huynh TT, Prodanov T, Lenders JWM, Timmers HJ, Benhammou JN, Linehan WM, Pacak K. Genetic screening for von Hippel - Lindau gene mutations in non-syndromic pheochromocytoma: low prevalence and false-positives or misdiagnosis indicates a need for caution. Horm Metab Res 2012; 44: in press
5. Elston MS, Meyer-Rochow GY, Holdaway I, Conaglen JV. Patients with RET D631Y mutations most commonly present with pheochromocytoma and not medullary thyroid carcinoma. Horm Metab Res 2012; 44: in press
6. Fishbein L, Bonner L, Torigian DA, Nathanson KL, Cohen DL, Pryma D, Cengel K. Combined 131I-MIBG and EBRT treatment provides durable local control in patients with malignant pheochromocytoma and paraganglioma. Horm Metab Res 2012; 44: in press
7. Gimenez-Roqueplo AP, Dahia PL, Robledo M. Update in the genetics of paraganglioma and pheochromocytoma and hereditary syndromes. Horm Metab Res 2012; 44: in press
8. Lahlou-Laforêt K, Consoli SM, Jeunemaitre X, Gimenez-Roqueplo AP. Presymptomatic genetic testing in minors at risk of paraganglioma and pheochromocytoma: our experience of oncogenetic multidisciplinary consultation. Horm Metab Res 2012; 44: in press
9. Lefebvre S, Borson-Chazot F, Kryza N,Wion N, Schillo F, Peix JL, Brunaud L, Finat A, Calender A, Giraud S. Screening of mutations in genes that predispose to hereditary paragangliomas and pheochromocytomas. Horm Metab Res 2012; 44: in press
10. Mannelli M, Dralle H, Lenders JWM. Perioperative management of pheochromocytoma/paraganglioma: is there a state of the art? Horm Metab Res 2012; 44: in press
11. Persu A, Lannoy N, Maiter D, Mendola A, Montigny P, Oriot P, VinckW, Garin P, Hamoir M, Vikkula M. Prevalence and spectrum of SDHx mutations in pheochromocytoma and paraganglioma from Belgium: an update. Horm Metab Res 2012; 44: in press
12. Plouin PF, Fitzgerald P, Rich T, Ayala-Ramirez M, Perrier ND, Baudin E, Jimenez C. Metastatic pheochromocytoma and paraganglioma: focus on therapeutics. Horm Metab Res 2012; 44: in press
13. Porzig A,Matthay KK, Dubois S, PampaloniM, Damon L, Hawkins R, Goldsby R, Hollinger F, Fitzgerald P. Proteinuria is associated with acute respiratory distress syndrome in patients with metastatic pheochromocytoma or paraganglioma. Horm Metab Res 2012; 44: in press
14. Spetz J, Dalmo J, Nilsson O, Wängberg B, Ahlman H, Forssell-Aronsson E. Specific binding and uptake of 131I-MIBG and 111In-octreotide in malignant paraganglioma - tools for choice of radionuclide therapy. Horm Metab Res 2012; 44: in press
15. Timmers HJ, Taieb D, Pacak K. Current and future anatomical and functional imaging approaches to pheochromocytoma and paraganglioma. Horm Metab Res 2012; 44: in press
16. Zelinka T, Petrák O, Hana T, Holaj R, Strauch B, Kršek M, Vránková A, Musil Z, Dušková J, Michalský D, Novák K, Widimskýjr. J. High incidence of cardiovascular complications in pheochromocytoma. Horm Metab Res 2012; 44: in press
17. Zovato S, Kumanova A, Demattè S, Sansovini M, Bodei L, Di Sarra D, Casagranda E, Severi S, Ambrosetti A, Schiavi F, Opocher G, Paganelli G. Peptide receptor radionuclide therapy (PRRT) in individuals with neck or mediastinal paraganglioma (PGL). Horm Metab Res 2012; 44: in press